VERA - VERA

에 대한 최신 뉴스 Vera Therapeutics (NASDAQ:VERA) 주식

VERA THERAPEUTICS INC

VERAMARK TECHS INC

Vera Therapeutics

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Equities

Macro Economic Events

Macro Notification

Market Summary

News

Sector ETFs

Politics

Treasuries

Economics

Markets

ETFs

COST

INTC

NFLX

NVDA

TSLA

VERA

미국 주식시장은 경제 모멘텀 둔화가 미국 기업들의 실적 전망에 영향을 미칠 수 있다는 투자자들의 우려로 이번 주에 5주 연속 상승세를 마감했다. 미국 경제는 1분기에 연율 1.3% 성장해 이전 추정치 1.6%보다 하향 조정되었다.

이번 주 시장 동향: 월가 5주 연속 상승 마감, 경제 성장 속도 감소, 트럼프의 유죄 평결 등

Southwest Gas Holdings Inc.

Biotech

Fintech news covering the emerging Financial Technology services sector

Fintech

Large Cap

Mid Cap

Health Care

Small Cap

Tech

$BTC

AVGO

CVNA

MSTR

SLNO

엔비디아(NASDAQ:NVDA)는 지난 1년간 수익률 순위에서 나스닥 100 지수 1위를 차지하며 눈에 띄는 기술 주식이었다.
이 칩 제조업의 거인은 인공지능(AI) 개발을 위한 칩에 대한 급증하는 수요로, 지난 2023년 5월 말 이후 무려 186%나 급등했다.

엔비디아는 1년 전 대비 186% 상승했지만, 다음의 7개 주식은 이보다 두 배 이상의 수익 기록

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics Inc

Vera Bradley Inc

Veracyte Inc

Veradigm Inc

VERALLIA,COURBEVOIE by VERALLIA, COURBEVOIE

Verallia

Veralto Corp

VERANO HLDGS CORP by Verano Holdings Corp.

Verano Holdings Corp

Verasity

Verastem Inc

Vera Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in patients with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">IgA Nephropathy (IgAN)</a>.
ORIGIN 3 follows the long-term results from the ORIGIN Phase 2b trial, which demonstrated sustained and substantial reductions in Gd-IgA1, hematuria, and proteinuria and showed stabilized kidney <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44625466/vera-therapeutics-completes-full-enrollment-in-pivotal-origin-phase-3-trial-for-atacicept-in-igan" rel="noreferrer noopener">function through 96 weeks</a>.
The company anticipates the 36-week primary efficacy endpoint data from the trial this quarter, which supports planned Biologics License Application (BLA) for accelerated approval to the U.S. FDA in the second half of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41577251/vera-therapeutics-atacicept-shows-sustained-substantial-improvement-in-kidney-function-for-patien" rel="noreferrer noopener">Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years</a>
Pending the submission and FDA review of the BLA, the company said it looks forward to a potential PDUFA date and commercial launch in 2026.
The ORIGIN 3 trial is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the safety and efficacy of atacicept in patients with IgAN who have persistent proteinuria and remain at high risk of disease progression.
Participants are randomized 1:1 to at-home self-administered once-weekly subcutaneous injections of atacicept 150 mg or placebo for a 104-week double-blind period, followed by a 52-week open-label extension.
The primary efficacy endpoint is the change in proteinuria as evaluated by urine protein to creatinine ratio (UPCR) through 36 weeks in an interim analysis of at least 200 participants.
The key secondary efficacy endpoint is a change in kidney function measured by estimated glomerular filtration rate (eGFR) through 104 weeks in the full study population.
In addition, the company is currently conducting the ORIGIN Extend trial, which provides extended access to atacicept for participants from the ORIGIN Phase 2b or Phase 3 trials until commercial availability in their region and captures longer-term safety and efficacy data.
<h2 class="wp-block-heading">Vera Therapeutics Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Vera Therapeutics, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Vera Therapeutics, the 200-day moving average sits at $37.56, according to <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">Benzinga Pro</a>, which is above the current price of $19.45. For more on charts and trend lines, <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: VERA stock is up 14.60% at $21.62&nbsp;at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/04/44717132/teledyne-secures-74-2m-us-army-contract-to-enhance-sensor-tech" target="_blank" rel="noreferrer noopener">Teledyne Secures $74.2M US Army Contract To Enhance Sensor Tech</a></li>
</ul>

General

Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch

<ul>
<li>On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)</li>
<li>U.S. FDA BLA submission for accelerated approval planned for 2H 2025</li>
</ul>
BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN).
"We are grateful for the IgAN community's strong interest in the clinical development of atacicept that helped drive us towards completing full enrollment in the ORIGIN 3 trial with a total of 431 participants. Complete enrollment represents another key milestone on the path to potential approval of the first B cell modulator targeting both BAFF and APRIL for IgAN," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "We anticipate the 36-week primary efficacy endpoint data from the trial this quarter, which supports our planned Biologics License Application for an accelerated approval to the U.S. FDA in the second half of 2025. ORIGIN 3 follows the positive long-term results from the ORIGIN Phase 2b trial that demonstrated sustained and substantial reductions in Gd-IgA1, hematuria and proteinuria, and showed stabilized kidney function through 96 weeks, positioning atacicept as a potential best-in-class IgAN therapy. Pending the submission and thorough FDA review of the BLA, we would look forward to a potential PDUFA date and commercial launch in 2026."
The ORIGIN 3 trial (NCT04716231) is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the safety and efficacy of atacicept in patients with IgAN who have persistent proteinuria and remain at high risk of disease progression. Participants are randomized 1:1 to at-home self-administered once-weekly subcutaneous injections of atacicept 150 mg or placebo for a 104-week double-blind period, followed by a 52-week open-label extension.
The primary efficacy endpoint is the change in proteinuria as evaluated by urine protein to creatinine ratio (UPCR) through 36 weeks in an interim analysis of at least 200 participants. The key secondary efficacy endpoint is change in kidney function as measured by estimated glomerular filtration rate (eGFR) through 104 weeks in the full study population.

Vera Therapeutics Announces Full Enrollment In ORIGIN Phase 3 Trial For Atacicept In IgAN

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Overweight and lowers the price target from $77 to $71.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $71

Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Buy and raises the price target from $59 to $61.

Guggenheim Maintains Buy on Vera Therapeutics, Raises Price Target to $61

Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) reported quarterly losses of $(2.75) per share which beat the analyst consensus estimate of $(2.83) by 2.83 percent. This is a 22.22 percent decrease over losses of $(2.25) per share from the same period last year.

Earnings

Vera Therapeutics FY 2024 GAAP EPS $(2.75) Beats $(2.83) Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Joel Beatty initiated coverage on Catalyst Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with an Outperform rating and announced a price target of $28. Catalyst Pharmaceuticals shares closed at $22.62 on Monday. <a href="https://www.benzinga.com/quote/CPRX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst John Freeman initiated coverage on Expand Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Strong Buy rating and announced a price target of $135. Expand Energy shares closed at $102.87 on Monday. <a href="https://www.benzinga.com/quote/EXE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst John Kim initiated coverage on Terreno Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) with a Market Perform rating and announced a price target of $71. Terreno Realty shares closed at $65.26 on Monday. <a href="https://www.benzinga.com/quote/TRNO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andy Chen initiated coverage on Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with an Outperform rating and announced a price target of $49. Vera Therapeutics shares closed at $36.54 on Monday. <a href="https://www.benzinga.com/quote/VERA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andy Chen initiated coverage on Oruka Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) with an Outperform rating and announced a price target of $20. Oruka Therapeutics shares closed at $13.70 on Monday. <a href="https://www.benzinga.com/quote/ORKA/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock.</a></li>
</ul>
Considering buying EXE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-1024x593.png" alt="" class="wp-image-764898" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Initiation

Pre-Market Outlook

Trading Ideas

CPRX

ORKA

TRNO

This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wolfe Research analyst Andy Chen initiates coverage on Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Outperform rating and announces Price Target of $49.

Wolfe Research Initiates Coverage On Vera Therapeutics with Outperform Rating, Announces Price Target of $49

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Viking Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)</h3>
<ul>
<li>On Jan. 17, HC Wainwright &amp; Co. analyst Joseph Pantginis reiterated Viking Therapeutics with a Buy and maintained a $102 price target.. The company' stock fell around 22% over the past month and has a <a href="https://www.benzinga.com/quote/VKTX">52-week low of $20.83</a>.</li>
<li>RSI Value: 28.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>VKTX Price Action: Shares of Viking Therapeutics gained 0.7% to close at $32.87 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">latest VKTX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138.png" alt="" class="wp-image-744179" style="width:593px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138-768x707.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<h3 class="wp-block-heading">Radnet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Jan. 15, Jefferies analyst Brian Tanquilut maintained RadNet with a Buy rating and lowered the price target from $100 to $80. The company's stock fell around 11% over the past five days and <a href="https://www.benzinga.com/quote/RDNT">has a 52-week low</a> of $35.16.</li>
<li>RSI Value: 25.2</li>
<li>RDNT Price Action: Shares of Radnet gained 0.6% to close at $60.19 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">trend in RDNT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="920" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139.png" alt="" class="wp-image-744183" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139-768x704.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">Vera Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>)</h3>
<ul>
<li>On Jan. 13, Vera Therapeutics secured an exclusive license from Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL. VT-109 offers broad therapeutic potential for B cell-mediated diseases, reinforcing Vera's position in B cell modulation. The company's stock fell around 20% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/VERA">low of $15.46.</a></li>
<li>RSI Value: 27.2</li>
<li>VERA Price Action: Shares of Vera Therapeutics gained 1% to close at $33.70 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">VERA shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140.png" alt="" class="wp-image-744188" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140-768x719.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Long Ideas

RDNT

VKTX

Top 3 Health Care Stocks That Could Blast Off This Quarter

Vera Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) shares are trading lower by 7.3% to $34.31 Monday afternoon. The company announced an <a href="https://www.benzinga.com/pressreleases/25/01/g42940821/vera-therapeutics-acquires-global-rights-to-novel-next-generation-dual-baffapril-inhibitor">exclusive license agreement</a> with Stanford University for VT-109.
What To Know: Vera Therapeutics has secured an exclusive license from Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL. VT-109 offers broad therapeutic potential for B cell-mediated diseases, reinforcing Vera&#8217;s position in B cell modulation.
CEO Marshall Fordyce highlighted the company&#8217;s commitment to leveraging its expertise to advance the molecule&#8217;s potential and improve outcomes for patients with severe autoimmune diseases. 
Under the agreement, Vera gains development and marketing rights for VT-109 in exchange for undisclosed upfront and milestone payments.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42953940/tuesdays-producer-inflation-report-could-stoke-market-volatility-as-fed-path-remains-unclear">Tuesday&#8217;s Producer Inflation Report Could Stoke Market Volatility As Fed Path Remains Unclear</a>
<h2 class="wp-block-heading">How To Buy VERA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Vera Therapeutics&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, VERA has a 52-week high of $51.61 and a 52-week low of $14.20.

What's Going On With Vera Therapeutics Stock?

WIIM

Vera Therapeutics shares are trading lower. The company announced an exclusive license agreement with Stanford University for VT-109.

Contracts

Vera Therapeutics Announced An Exclusive License Agreement With Stanford University For Fusion Protein Targeting BAFF And APRIL, Known As VT-109, With Therapeutic Potential Across The Spectrum Of B Cell-mediated Diseases For Undisclosed Upfront And Milestone Payments

Wells Fargo analyst Mohit Bansal initiates coverage on Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Overweight rating and announces Price Target of $70.

Wells Fargo Initiates Coverage On Vera Therapeutics with Overweight Rating, Announces Price Target of $70

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Neutral and raises the price target from $30 to $38.

Wedbush Maintains Neutral on Vera Therapeutics, Raises Price Target to $38

Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.64) by 32.81 percent. This is a 88.89 percent decrease over losses of $(0.45) per share from the same period last year.

Earnings Misses

Vera Therapeutics Q3 EPS $(0.85) Misses $(0.64) Estimate

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Overweight and raises the price target from $72 to $75.

JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $75

Reported Earlier, Vera Therapeutics Prices $300M Public Offering Of 7,142,858 Class A Common Shares At $42/Share

Vera Therapeutics shares are trading lower after the company announced plans to commence a public offering to issue and sell $300 million of its Class A common stock.

In connection with the proposed offering, Vera expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock sold in the public offering.&nbsp;

Offerings

Vera Therapeutics Plans To Commence Public Offering To Issue And Sell $300M Of Shares Of Its Class A Common Stock

Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Buy and raises the price target from $56 to $64.

Guggenheim Maintains Buy on Vera Therapeutics, Raises Price Target to $64

On Saturday, Vera Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) released data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN), which showed stabilized kidney function through 96 weeks <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41562227/vera-therapeutics-announces-96-week-egfr-stabilization-in-origin-phase-2b-study-of-atacicept-in-ig" rel="noreferrer noopener">of long-term follow-up</a>.
These data were presented in a late-breaking oral presentation at the American Society of Nephrology Kidney Week 2024 and published in a&nbsp;manuscript&nbsp;in the&nbsp;Journal of the American Society of Nephrology.
Over 96 weeks, participants treated with atacicept demonstrated a -66% reduction in galactose-deficient IgA1 (Gd-IgA1), resolution of hematuria in 75% of participants, a -52% reduction in proteinuria, and a mean annualized estimated glomerular filtration rate (eGFR) slope of -0.6 mL/min/1.73m2/year.
The cumulative generally favorable safety profile of atacicept remained consistent with that observed during the randomized period, with a 90% completion rate of atacicept treatment.
The company says these data support the potential for atacicept to offer long-term, comprehensive IgAN disease modification and provide further confidence in the ongoing pivotal Phase 3 ORIGIN 3 trial of atacicept in IgAN.
The company plans to initiate an ORIGIN Extend study in the fourth quarter of 2024, which will provide ORIGIN participants with extended access to atacicept before its commercial availability.
The ORIGIN 3 trial is on track to announce topline results in the second quarter of 2025, with planned FDA marketing application submission later in the year.
Earlier this year, Vera Therapeutics revealed 72-week data from the open-label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN).&nbsp;
Data from the OLE showed the consistent and sustained reductions of serum galactose-deficient IgA1 (Gd-lgA1), hematuria, and urine protein to creatinine ratio (UPCR), as well as the stability of eGFR over 72 weeks&nbsp;in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36807507/whats-going-on-with-vera-therapeutics-stock-today" rel="noreferrer noopener">participants with IgAN</a>.&nbsp;
Price Action: VERA stock is up 12.2% at $46.12 at last check Monday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41571498/gryphon-digital-restructures-18-million-debt-with-lender-anchorage-grants-it-board-seat" target="_blank" rel="noreferrer noopener">Gryphon Digital Restructures $18 Million Debt With Lender Anchorage, Grants It Board Seat</a></li>
</ul>

Movers

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Press Releases

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Disc Medicine

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mesoblast Limited - American Depositary Shares

Mesoblast

MannKind

Novavax

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vericel

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

JP Morgan

Guggenheim

Wolfe Research

Wells Fargo

Wedbush

미국 주식시장은 경제 모멘텀 둔화가 미국 기업들의 실적 전망에 영향을 미칠 수 있다는 투자자들의 우려로 이번 주에 5주 연속 상승세를 마감했다.
미국 경제는 1분기에 연율 1.3% 성장해 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39090782/is-q1-gdp-data-easing-pressure-on-fed-to-cut-interest-rates-5-economists-weigh-in" target="_blank" rel="noopener">이전 추정치 1.6%</a>보다 하향 조정되었다.
연방준비제도(연준)가 선호하는 인플레이션 조치는 4월에도 안정적으로 유지되어 <a href="https://www.benzinga.com/markets/equities/24/05/39113676/are-rate-cuts-imminent-after-feds-preferred-inflation-data-holds-steady-be-careful-what-you-wish" target="_blank" rel="noopener">가격 압박 재개</a>에 대한 우려가 완화되었다. 그러나 지출 및 소득 증가 둔화는 소비자 건전도의 약화를 의미하는 동시에 시카고 비즈니스 활동 지표가 2020년 5월 이후 최저 수준으로 급락하여 최종 사이클 둔화 가능성에 대한 우려를 불러일으켰다.
유틸리티 섹터는 유틸리티 셀렉트 섹터 SPDR 펀드(NYQ:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)의 유럽채권분석가 A의 상방 타깃 주가에서 약 3% 상승한 74달러로 유지되면서 이번 주에 상승했습니다.
Technology Select Sector SPDR Fund(ARCA:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/xlk" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for XLK">XLK</a>)가 추적한 기술 부문은 이번 주 최악의 실적을 보인 반면, Utilities Select Sector SPDR Fund(ARCA:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/xlu" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for XLU">XLU</a>)가 추적한 유틸리티 부문은 투자자들이 방어 부문에 초점을 맞추면서 우수한 성과를 보였다.
<h2 class="wp-block-heading">트럼프 주식, 침체</h2>
트럼프 미디어 &amp; 테크놀로지 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)의 주가는 도널드 트럼프 전 대통령이 사업 기록 위조와 관련된 34건의 혐의로 <a href="https://www.benzinga.com/general/politics/24/05/39100065/trump-found-guilty-on-all-34-counts-in-hush-money-criminal-trial-heres-what-happens-next">유죄</a> 판결을 받은 후 하락했다. 일부 투자자들의 강력한 지지에도 불구하고 이 회사의 재무 성과에 대한 우려와 트루스 소셜(Truth Social)의 사용자 참여 감소가 <a href="https://www.benzinga.com/news/24/05/39108913/whats-going-on-with-former-president-donald-trump-backed-djt-stock-on-friday" target="_blank" rel="noopener">투자 심리에 영향</a>을 미쳤다.
<h2 class="wp-block-heading">엔비디아 가치 급등</h2>
엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)의 시가총액은 2조 8050억 달러로 급증하여 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), 엑슨 모빌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), 월마트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), 코스트코 홀세일즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), 넷플릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), 월트 디즈니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) 및 펩시코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>)의 합산 가치를 넘어섰다. 엔비디아의 AI 기술 발전과 일론 머스크의 <a href="https://www.benzinga.com/general/education/24/05/39049904/nvidia-now-worth-more-than-tesla-exxon-walmart-costco-netflix-intel-disney-and-pepsi-combined-t" target="_blank" rel="noopener">슈퍼컴퓨팅 프로젝트</a>에서의 제품 사용 가능성에 부분적으로 힘입어 투자자 신뢰가 높아짐에 따라 이 회사 주가가 사상 최고치를 경신했다.
<h2 class="wp-block-heading">사상 최고의 주택가격</h2>
미국 주택 가격은 2024년 3월 전년 동기 대비 7.4% 상승해 사상 최고치를 기록해 1년여 만에 가장 빠른 성장률을 기록했다. 샌디에이고가 연간 11.1%의 상승률을 기록하며 선두를 달리고 있으며 <a href="https://www.benzinga.com/markets/equities/24/05/39040957/us-home-prices-hit-all-time-highs-fastest-growth-rate-in-a-year-weve-witnessed-records-repeatedl" target="_blank" rel="noopener">뉴욕과 클리블랜드</a>가 그 뒤를 이었다.
<h2 class="wp-block-heading">엔비디아를 뛰어넘는 주식들</h2>
엔비디아의 주식은 지난 1년 동안 186%나 급등했으며, 이는 AI 칩 수요에 의해 촉진되었다. 베라 테라퓨틱스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/vera" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for VERA">VERA</a>) 및 머니라이언(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/ml" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ML">ML</a>)을 포함한 다른 7개 미국 주식은 엔비디아의 수익률을 두 배 이상 늘렸다. 이들 기업은 생명공학, 핀테크, 소매업의 발전으로 혜택을 누리며 <a href="https://www.benzinga.com/general/biotech/24/05/39075857/nvidia-is-up-186-from-a-year-ago-yet-these-7-stocks-have-more-than-doubled-their-returns-over-the" target="_blank" rel="noopener">다양한 산업 성장</a>을 보여주었다.
<h2 class="wp-block-heading">바이든의 정전 계획</h2>
조 바이든 대통령은 금요일, 평화 유지와 인질 석방을 위한 로드맵을 강조하면서 이스라엘과 하마스 간의 포괄적인 휴전 협정을 제안했다. 이 계획에는 휴전, 포로 교환, 국제 협력을 통한 가자지구 재건이 포함된다.
사진: 셔터스톡

엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)는 지난 1년간 <a href="https://www.benzinga.com/quote/NVDA/news" target="_blank" rel="noopener">수익률 순위</a>에서 나스닥 100 지수 1위를 차지하며 눈에 띄는 기술 주식이었다.
이 칩 제조업의 거인은 인공지능(AI) 개발을 위한 칩에 대한 급증하는 수요로, 지난 2023년 5월 말 이후 무려 186%나 급등했다.
베테랑 월스트리트 투자자 에드 야데니(Ed Yardeni)는 최근 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39037833/magnificent-7-becomes-the-magnificent-one-wall-street-guru-hails-single-tech-stock-">매그니피센트 7</a>(Magnificent Seven)과 엔비디아의 탁월한 성능을 차별화하기 위해 &#8216;매그니피센트 1(Magnificent One)&#8217;을 만들었다.
엔비디아의 시장 가치 증가 규모를 설명하기 위해 불과 1년 전만 해도 엔비디아의 가치는 1조 달러로 평가되었다. 오늘날 이 회사는 2조 8천억 달러라는 엄청난 가치를 자랑하며 미국에서 세 번째로 큰 회사가 되었다.
엔비디아의 현재 가치는 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), 브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), 월마트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) 및 마스터카드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>)의 시장가치 합계와 동일하다.
자세히 보기: <a href="https://www.benzinga.com/general/education/24/05/39063462/when-will-nvidia-be-the-most-valuable-company-in-the-world">엔비디아가 세계에서 가장 가치 있는 회사가 될 때는 언제일까?</a>
그러나 엔비디아의 눈부신 상승세는 지난 1년간 이 칩 제조업체의 인상적인 수익률을 두 배 이상 증가시킨 미국 주식 7개에 의해 가려졌다.
<h2 class="wp-block-heading">7. 베라 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>)- 363%</h2>
베라 테라퓨틱스는 심각한 면역 질환에 대한 혁신적인 치료제 개발에 전념한 바이오제약 기업이다. 이 회사의 주식은 임상 프로그램의 진전과 약품 후보물질에 대한 낙관적인 예상으로 급등했다.
2023년 5월 30일 이후 363%의 급등을 기록했으며, 동일 기간 동안 엔비디아의 수익률을 두 배로 능가했다.
<h2 class="wp-block-heading">6. 버티브 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>)- 413%</h2>
버티브 홀딩는 중요한 디지털 인프라 및 연속성 솔루션을 제공한다. 이 회사는 데이터 센터 및 IT 인프라에 대한 수요가 증가한 데에 힘입어 강력한 재무 성과를 거두고, 결과적으로 주가가 크게 상승했다.
<h2 class="wp-block-heading">5. 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)- 441%</h2>
마이크로스트레티지는 비즈니스 인텔리전스 기업으로, 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)에 대한 상당한 투자로 주목받았다.
이 회사의 주식 수익률 비트코인 가격 변동과 밀접한 관련이 있으며, 주가는 비트코인의 상승과 함께 급등했다. 이 가장 큰 암호화폐는 지난 2023년 5월 말 이후 140%의 상승을 기록했다.
<h2 class="wp-block-heading">4. 애버크롬비 &amp; 피치(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>)- 503%</h2>
애버크롬비 &amp; 피치는 캐주얼 웨어 및 라이프스타일 제품으로 유명한 명품 패션 리테일러이다. 이 회사의 주가 강세는 강력한 전환 노력, 강력한 전자상거래 성장 및 개선된 수익성 지표로 인해 투자자의 관심을 끌었다.
<h2 class="wp-block-heading">3. 카바나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NASDAQ">CVNA</a>)- 666%</h2>
카바나는 온라인 중고차 리테일러로, 자택 배달 및 7일 내 반품 정책을 갖춘 완전 온라인 플랫폼을 통해 차량 구매 경험을 혁신하였다.
이 회사는 어려웠던 시기를 겪은 지속적인 회복과 특별한 사업 모델 및 성장 가능성에 대한 투자자의 신뢰회복으로 주가가 급등했다.
<h2 class="wp-block-heading">2. 솔레노 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>)- 697%</h2>
솔레노 테라퓨틱스는 프라더 윌리(Prader-Willi) 증후군과 같은 희귀 질병에 대한 치료제 개발에 초점을 맞춘 회사이다. 이 회사의 주식은 긍정적인 임상 시험 결과와 약품 후보물질 파이프라인에 대한 낙관적 전망으로 인해 급등했다.
<h2 class="wp-block-heading">1. 머니라이언(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>)- 790%</h2>
머니라이언는 개인 대출, 신용 빌딩 서비스 및 금융 자문 도구를 비롯한 다양한 제품을 제공하는 디지털 금융 플랫폼이다. 이 회사의 상당한 주가 급등은 핀테크 서비스의 공격적인 확장과 혁신에 의해 주도되었으며, 접근 가능한 금융 솔루션을 찾는 광범위한 고객 기반에 어필하고 있다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-361859" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/29161150/image-119-1024x500.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/29161150/image-119-1024x500.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/29161150/image-119-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/29161150/image-119-768x375.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/29161150/image-119-1536x750.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/29161150/image-119.png 1920w" alt="" width="1024" height="500" /></figure>
사진: 셔터스톡
놓치지 마세요: 미국 평균 부부의 퇴직을 위한 저축액 &#8211; 얼마나 모으셨나요? <a href="http://www.benzinga.com/money/smartasset" target="_blank" rel="noreferrer noopener">비교해보세요</a>

Comments

Vera Therapeutics

뉴스

에 대한 최신 뉴스 Vera Therapeutics (NASDAQ:VERA) 주식

토요일, 6월 01, 2024

수요일, 5월 29, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌